Bryan Sclerosol for prevention of recurrent malignant pleural effusion to be launched by March.
Executive Summary
BRYAN SCLEROSOL FOR MALIGNANT PLEURAL EFFUSIONS SET FOR LAUNCH BY MARCH, the Woburn-Mass.-based company said following FDA approval of the intrapleural aerosol talc product Dec. 24. Sclerosol is indicated for use during thoracoscopy or open thoracotomy "to prevent recurrence of malignant pleural effusions in symptomatic patients."
You may also be interested in...
Carbaglu Does Not Set Precedent For Orphan Drugs To Skip Trials, FDA Says
FDA is not setting a precedent by considering Orphan Europe's orphan drug Carbaglu for approval without a clinical trial, FDA's Office of Drug Evaluation III Director Julie Beitz indicated after the Endocrine and Metabolic Drugs Advisory Committee's Jan. 13 vote for approval
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011